以世界級研發能量及量產技術
打造亞洲華人創新抗體藥物標竿企業

聯合生物製藥是一家以創新為導向
單株抗體藥物開發、製造與銷售全方位生物製藥公司。
2017年於新竹工業園區全新落成的台灣第一大蛋白質藥廠,除擁有高端的研發設備,2條2000公升產線,未來更可擴充至24,000公升產線 聯生藥卓越的抗體藥物研發與製藥技術,將引領亞洲抗體藥物產業邁進嶄新里程碑。

Our Integrated Technology Platform

UBP possesses high value technology platform: A fully integrated monoclonal antibody (mAb) drug development technology which enables us to generate stable, high productivity, and serum free clones for industrial scale mAb production. Our competitive cell and protein process development, characterization, analytical and formulation method allow us to develop high titer, robust and scalable cell culture and protein fermentation resulting in optimized-yield, high quality and robust purification process for our produced antibodies.

 

新聞活動

聯生藥新聞

  • 2019/06/11
    聯生藥治療單純皰疹病毒抗體新藥UB-621獲美國FDA核准 執行臨床2期復發型生殖器皰疹試驗
  • 2019/09/02
    聯生藥2,000L蛋白質藥廠通過TFDA PIC/S GMP查廠
  • 2019/10/07
    Interview with Chang-Yi Wang for Taiwan HCLS

UBP Protein Drug Facility opening (ENG)

UBP 蛋白質藥廠開幕影片

投資人下載專區

More
More